EMA Executive Director Recruitment: Leading the Future of Medicines Regulation

By João L. Carapinha

February 23, 2026

The EMA Executive Director Recruitment procedure has opened, a pivotal role overseeing operations like medicine authorizations, safety monitoring, and EU-wide public health responses. This vacancy, with reference COM/2026/20118, reports to the EMA Management Board, managing a 2025 budget of about EUR 600 million and 900 staff in a multilingual, multicultural setting in Amsterdam. As a Temporary Agent at grade AD 14, it offers a five-year renewable mandate under Regulation (EC) No 726/2004, seeking candidates with deep management expertise.

Core Leadership Duties

The Executive Director’s responsibilities include daily administration, staff leadership, strategic planning, budget management, and stakeholder relations that support EMA’s scientific and regulatory work. Selection emphasizes proven skills in managing large teams through changes like digital transformation, upholding multidisciplinary scientific evaluations, and advancing EMA’s global mission. Required expertise covers EU medicines laws, risk analysis (assessment, management, communication), and finances, plus strengths in healthcare sciences or pharmacology from public roles engaging pharma. This enables oversight of controls and partnerships with EU bodies, Member States, and international allies. Learn more in the official recruitment notice. Applications close 19 March 2026 via the EU portal

Reference url

Recent Posts

Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis

By HEOR Staff Writer

March 16, 2026

Cancer productivity losses from premature mortality and morbidity due to leading cancers across 28 European countries in 2022 totaled €39.8 billion, as estimated via the human capital approach in this study....
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Voxzogo reimbursement Netherlands hangs in limbo after Biomarin's decision on March 12, 2026, to withdraw its application, leaving children with achondroplasia without access despite parental pleas.
Catalyzing Cardiovascular Health Innovation through Urban Interventions and Collaborative Research

By HEOR Staff Writer

March 12, 2026

Cardiovascular health innovation is at the forefront of the Innovative Health Initiative (IHI), the world's largest public-private partnership in life sciences, which succeeds the Innovative Medicines Initiative (IMI). Key projects from IHI Call 8, such as Cities@Heart, target cardiovascular dise...